Concert Pharmaceuticals
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
65 Hayden Ave Ste 3000N, Lexington, Mass...Phone Number
(781) 860-0045Website
www.concertpharma.comRevenue
$32.6 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Concert Pharmaceuticals
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company's approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert's pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Concert Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Concert Pharmaceuticals
Check out if Concert Pharmaceuticals is spiking on competitors!
Earning: See what the market has to say on Concert Pharmaceuticals recently announced quarterly report
Click to see if Concert Pharmaceuticals had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Concert Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Concert Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Concert Pharmaceuticals launches new products
Funding: Get notified immidiatlly once Concert Pharmaceuticals has new funding data
Recommended Actions
Find VP level buyers at Concert Pharmaceuticals
Find more new buyers
Compare Similar Companies to Concert Pharmaceuticals
Compare insights from companies similar to Concert Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Concert Pharmaceuticals
$32.6M
51-200
Private
$278.5M
2006
N/A
Company Profile Activity
Activity Insights
Concert Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Concert Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Concert Pharmaceuticals.
Concert Pharmaceuticals financials insights
Gather financial insights about Concert Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2006
Series A
$10M
Series B
$48.5M
2008
Series C
$37M
2011
Corporate Investment
$4M
2014
Stock Offering
$84M
2017
Debt
$30M
2021
Other Financing Round
$65M
Concert Pharmaceuticals Tech Stack
A closer look at the technologies used by Concert Pharmaceuticals
Most Recent Scoops
Mergers & Acquisitions (M&A)
Open Position
Left Company
Executive Move
Funding
Project
Concert Pharmaceuticals News & Media
Sun Pharma Completes Acquisition of Concert Pharmaceuticals
Acquisition Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, to Sun Pharma's Global Dermatology Portfolio MUMBAI, India and PRINCETON, N.J., March 6, 2023 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO,...Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert maintains deuruxolitinib breakthrough therapy designation from FDA for the treatment of alopecia areata.CNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) to Sun Pharmaceutical Industries Limited is fair to Concert shareholders. Per the terms of the agreement, Sun Pharma would acquire Concert for an upfront payment of $8.00 per share in cash, plus a non-tradeable contingent value right entitling Concert shareholders to receive up to an additional $3.50 per share in cash, payable upon deuruxoliSHAREHOLDER ALERT: Weiss Law Investigates Concert Pharmaceuticals, Inc.
NEW YORK, Jan. 19, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Concert Pharmaceuticals, Inc. ("Concert" or the "Company") (NASDAQ: CNCE), in connection with the proposed acquisition of the...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Concert Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company's approach starts with previously studied compounds, including approved drugs, in which deuterium... Read More
